Phuturdex › Diseases › Brain Neoplasms
Drugs in development · updated 30 October 2026
Brain Neoplasms: drugs in development
As of 30 October 2026 there are 217 active clinical trials (recruiting or ongoing, phases I–III) on 190 drugs for brain Neoplasms. 72 are experimental, that is not yet approved in the United States.
Summary updated every week · data as of 30 October 2026. In Phuturdex you get the full detail of every drug and an email when an alert is published on the ones you follow.
Sign in free →Experimental drugs
Not yet approved by the US FDA for any indication.
Sorted by most advanced phase and number of active trials. Showing 40 of 72 drugs.
Approved drugs in new trials
Approved by the US FDA for at least one indication, not necessarily this disease, and now in active trials on it.
| Drug | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| TemozolomideTemodal, Temodar | III | 24 | NCT00978458 |
| PembrolizumabKEYTRUDA, MK-3475 | III | 16 | NCT05317858 |
| NivolumabOpdivo, ONO-4538 | III | 15 | NCT05317858 |
| Bevacizumabavastin, MVASI | III | 13 | NCT06888817 |
| IpilimumabYERVOY, ipililumab IV | III | 11 | NCT05317858 |
| MemantineNamenda, Memantine Mylan® | III | 6 | NCT04804644 |
| Trastuzumab deruxtecanDS-8201a, DS-8201 | III | 5 | NCT04739761 |
| EntrectinibRozlytrek® | II–III | 4 | NCT05770544 |
| DexamethasoneDexametasone, Dextenza | II–III | 3 | NCT07542288 |
| LevetiracetamSpritam®, Elepsia Xr® | III | 3 | NCT06442748 |
| 18F-DOPA18F-FDOPA, Fluorodopa F 18 | III | 2 | NCT04706910 |
| AtezolizumabTecentriq, MPDL3280A | III | 2 | NCT05317858 |
| CemiplimabREGN2810, Libtayo® | III | 2 | NCT05317858 |
| NiraparibZejula® | III | 2 | NCT06388733 |
| CarvedilolCoreg Cr®, Coreg® | III | 1 | NCT03418961 |
Sorted by most advanced phase and number of active trials. Showing 15 of 118 drugs.
All 190 drugs, with the details
In Phuturdex every drug has all its trials, sponsors and countries, FDA and EMA approvals, orphan designations and safety alerts. Free until 31 March 2027.
Open in Phuturdex →Specific forms
- Diffuse Intrinsic Pontine Glioma 40 drugs
- Glioma 184 drugs
- Medulloblastoma 77 drugs
- Glioblastoma 245 drugs
- Astrocytoma 64 drugs
- Central nervous system neoplasm 70 drugs
- Pinealoma 21 drugs
- Primitive neuroectodermal tumor 31 drugs
- Gliosarcoma 34 drugs
- Ependymoma 56 drugs
- Rhabdoid tumor 52 drugs
- Neuroblastoma 95 drugs
Broader categories
- Nervous System Diseases 39 drugs
- Brain Diseases 23 drugs
- Central nervous system disease 38 drugs
- Nervous system neoplasm 4 drugs
- Central nervous system neoplasm 70 drugs
- Neoplasm 671 drugs
Source: Phuturdex analysis of ClinicalTrials.gov data (U.S. National Library of Medicine), updated 30 October 2026. Active trials = recruiting or ongoing, phases I–III, with at least one identified drug; phase and sites refer to the trials on this disease. Disease name: NLM MeSH; NLM MeSH term: D001932 “Brain Neoplasms”.